Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually.
Headquartered in Somerset, New Jersey, the company is listed on NYSE and included in S&P 500 Index having generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™